Journey Medical Corp.’s DFD-29, partnered with Dr. Reddy's Laboratories Ltd., has potential to claim a significant share of the papulopustular rosacea market, which Galderma S.A.’s Oracea (doxycycline) currently dominates, having originally won US Food and Drug Administration approval in 1967. Topline results from Phase III clinical trials showed a statistically significant efficacy advantage for the drug over both Oracea and placebo in terms of reducing lesion count in adult patients with the skin condition.
Don’t Stop Relieving: Journey’s DFD-29 Trounces Oracea In Reducing Rosacea Lesions
The company posted positive topline results from the Phase III MVOR-1 and MVOR-2 trials comparing DFD-29 against Galderma’s drug in papulopustular rosacea.
